Cryoport, Inc. Provides Revenue Guidance for the Year 2022
August 04, 2022 at 04:05 pm EDT
Share
Cryoport, Inc. provided revenue guidance for the year 2022. For the year, the company expects that its revenue guidance for the full year 2022 of $260 - $265 million will be driven primarily by the record demand for dewars, cryogenic freezer, and shipper systems and solutions; growth from the company's support of global clinical trials and commercially launched therapies from the company's cell and gene therapy clients.
Cryoport, Inc. is engaged in supply chain solutions for cell and gene therapies. The Companyâs supply chain solutions enable manufacturers, contract manufacturers (CDMOâs), contract research organizations (CROâs), developers, and researchers to carry out their business with certainty. The Company provides a broad array of supply chain solutions for the life sciences industry. Through its platform of critical products and solutions, including advanced temperature-controlled packaging, informatics, specialized bio-logistics services, bio-storage, bio-services, and cryogenic systems, the Company is enabling the future of medicine worldwide, through its systems, compliant procedures, and approach to supply chain management. Its products and services include Cryoport Express Shippers, Cryoport ELITE Shipper Systems, Cryoport Consulting Services, Cryoport Bioservices, CRYOGENE, CRYOPDP Temperature-controlled Logistics, Cryoport Cryoshuttle, IntegriCell Services, Tec4Med, and others.
CRYOPORT, INC. 
